Kalobios Selects POTELLIGENT® CHOK1SV Cell Line for the Research, Development and Manufacture of Humaneered™ Antibodies

February 08,2011 Princeton, NJ, USA and Basel, Switzerland

KaloBios Pharmaceuticals, Inc., has signed a research and commercial agreement with BioWa, Inc. and Lonza to use their POTELLIGENT® CHOK1SV cell line for the development and production of its Humaneered™ antibodies.

POTELLIGENT® CHOK1SV is a new host cell line for manufacturing recombinant antibodies that combines the power of BioWa’s engineered glycosylation POTELLIGENT® Technology with the advantages of Lonza’s proprietary GS Gene Expression System™, which includes the industry-leading cell line CHOK1SV.

“We are gratified by the confidence that Kalobios displays in selecting the POTELLIGENT® CHOK1SV cell line as its production host for its innovative treatments”, said Janet White, Head of Development Services at Lonza. “We look forward to working with Kalobios to meet its manufacturing needs and to continuing our successful, long-lasting collaboration.”

“We are pleased with KaloBios’ activities using the POTELLIGENT® technology. Their progression to POTELLIGENT® CHOK1SV is an indicator of the opportunity ahead for their candidate”, said Dr. Masamichi Koike, President and CEO of BioWa.


Advantages of the POTELLIGENT® CHOK1SV Cell Line

  • The POTELLIGENT® CHOK1SV cell line retains the desirable features of a high-productivity cell line (robust, high-yielding, scalable)
  • Proven bioprocess platform for CHOK1SV is repeatable in the new cell line
  • Antibodies produced by the new cell line:
    • Exhibit enhanced antibody dependent cellular cytotoxicity (ADCC)
    • Can exert potent cytotoxic effects when their target antigen is low-density
    • Work in whole blood
    • Retain all the other desirable features of antibodies

 

The POTELLIGENT® CHOK1SV cell line is available as one of the options in Lonza cell line construction offerings. To learn more about the benefits of POTELLIGENT® CHOK1SV, please contact one of our experts at +44 (0) 1753 777 000 or GSLonza@lonza.com

About Lonza
Lonza is one of the world's leading suppliers to the pharmaceutical, healthcare and life science industries. Products and services span its customers’ needs from research to final product manufacture. It is the global leader in the production and support of active pharmaceutical ingredients both chemically as well as biotechnologically. Biopharmaceuticals are one of the key growth drivers of the pharmaceutical and biotechnology industries. Lonza has strong capabilities in large and small molecules, peptides, amino acids and niche bioproducts which play an important role in the development of novel medicines and healthcare products. In addition, Lonza is a leader in cell-based research, endotoxin detection and cell therapy manufacturing. Furthermore, the company is a leading provider of value chemical and biotech ingredients to the nutrition, hygiene, preservation, agro and personal care markets.

Lonza is headquartered in Basel, Switzerland and is listed on the SIX Swiss Exchange. In 2010, the company had sales of CHF 2.680 billion. Further information can be found at www.lonza.com.

About BioWa, Inc.
BioWa is a wholly owned subsidiary of Kyowa Hakko Kirin Co., Ltd., Japan's leading pharmaceutical and largest biotech company, and is the exclusive worldwide licensor of the AccretaMab® platform. The AccretaMab® platform consists of POTELLIGENT® and COMPLEGENT® Technologies, creating a superior antibody molecule with enhanced ADCC and CDC activities. BioWa is offering POTELLIGENT® and COMPLEGENT® Technologies to partners under a license to maximize the value of these technologies. Together with Kyowa Hakko Kirin, BioWa is committed to promote ADCC/CDC enhanced monoclonal antibody-based therapeutics to fight cancer and other life-threatening and debilitating diseases. For more information about BioWa, visit its web site at www.biowa.com. POTELLIGENT®, COMPLEGENT®, and AccretaMab® are the trademarks of Kyowa Hakko Kirin Co., Ltd. All rights are reserved.

About POTELLIGENT® Technology
POTELLIGENT® Technology improves potency and efficacy of antibody therapeutics, by enhancing ADCC, one of the major mechanisms of action for antibody therapeutics. POTELLIGENT® Technology involves the reduction of the amount of fucose in the carbohydrate structure of an antibody using a proprietary fucosyltransferase-knockout CHO cell line as a production cell. Research shows that POTELLIGENT® Technology dramatically enhances ADCC activity of an antibody in vitro, and significantly increases potency and efficacy of the antibody in vivo. A number of POTELLIGENT® antibodies are being investigated in human clinical trials.

About the GS Gene Expression System™
The GS Gene Expression System™, which is owned and licensed by Lonza, is used for the production of therapeutic recombinant proteins and monoclonal antibodies. Nearly 100 biotechnology and pharmaceutical companies and over 75 academic laboratories worldwide are successfully using the GS Gene Expression System™ which has established itself as the industry standard. This system is characterized by its speed and ease of use. In addition, the higher yielding cell lines provide cost-efficient production of therapeutic proteins.

Humaneered™ is a trademark of KaloBios Pharmaceuticals, Inc.

Browse All News
Bg